SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

Patients with chronic kidney disease (CKD) and heart failure have higher rates of inpatient dialysis initiation than those without heart failure.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Patients who undergo surgery immediately preceding the weekend have an increased risk for complications, readmission, and mortality at 30 days, 90 days, and one year compared with those undergoing ...

Comorbid lung function impairment was associated with increased risks for cardiovascular disease and mortality in type 2 diabetes.

Breast cancer survivors who receive chemotherapy may experience greater physical health decline than those who receive endocrine therapy alone.

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.